Company profile: Alpine Immune Sciences
1.1 - Company Overview
Company description
- Provider of protein-based immunotherapies for autoimmune and inflammatory diseases, using a proprietary directed evolution platform to engineer native immune proteins into multi-targeted therapeutics. Pipeline includes povetacicept (ALPN-303), a dual BAFF/APRIL antagonist, and acazicolcept (ALPN-101), a dual CD28/ICOS antagonist; conducts clinical trials on investigational therapies.
Products and services
- Acazicolcept (ALPN-101): Investigational, dual CD28/ICOS antagonist engineered to treat severe inflammatory diseases, including systemic lupus erythematosus, within Alpine’s protein-based immunotherapy portfolio
- Directed Evolution Platform: Proprietary platform that engineers native immune system proteins into differentiated, multi-targeted therapeutics for serious diseases, supporting research and development of protein-based immunotherapies
- Povetacicept (ALPN-303): Investigational, dual antagonist of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL), targeting multiple autoimmune diseases with protein-based therapeutic design
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alpine Immune Sciences
Cyxone
HQ: Sweden
Website
- Description: Provider of biopharmaceutical R&D focused on cyclotide-based drugs for severe autoimmune diseases. Operates via an international expert network across research, development and manufacturing. Pipeline includes Rabeximod, an oral Phase 2 candidate for rheumatoid arthritis targeting inflammatory macrophages, and T20K, an early clinical candidate for multiple sclerosis modulating T cell activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyxone company profile →
iBio
HQ: United States
Website
- Description: Provider of AI-driven drug discovery and antibody therapeutic development solutions, including a discovery platform to validate difficult targets and develop antibody therapeutics; patented Epitope Engineering Engine; fully human antibody library; StableHu Antibody Optimizer; EngageTx CD3 T-cell engager panel; and a pipeline of immuno-oncology and other therapeutic candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iBio company profile →
MyMD Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage pharmaceuticals, including MYMD-1, an oral TNF-alpha inhibitor to regulate the immune system, reduce chronic inflammation, and potentially treat autoimmune and age-related conditions; and Supera-CBD, a synthetic cannabidiol analog targeting CB2 receptors for anxiety, chronic pain, seizures, and potentially addiction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MyMD Pharmaceuticals company profile →
Novellus Therapeutics
HQ: United States
Website
- Description: Provider of engineered cellular medicines using non-immunogenic mRNA molecules to safely and efficiently reprogram and gene-edit cells, engineering precision medicines for patient segments via a technology toolbox spanning in vivo and ex vivo applications, including allogeneic and autologous approaches.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novellus Therapeutics company profile →
Citryll
HQ: The Netherlands
Website
- Description: Provider of pharmaceutical drugs targeting Neutrophil Extracellular Traps (NETs) to treat autoimmune and inflammatory diseases such as SLE, RA, vasculitis, and IPF. Offers CIT-013, a therapeutic antibody; conducts NETosis inhibition research to reduce auto-antigen release and clear pro-inflammatory NETs; advances clinical development with first-in-human and planned Phase 2a trials in RA and hidradenitis suppurativa; and pursues collaboration opportunities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Citryll company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alpine Immune Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alpine Immune Sciences
2.2 - Growth funds investing in similar companies to Alpine Immune Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alpine Immune Sciences
4.2 - Public trading comparable groups for Alpine Immune Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →